Epizyme, Inc. (EPZM)
(Delayed Data from NSDQ)
$12.10 USD
+0.19 (1.60%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.10 USD
+0.19 (1.60%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Is Epizyme (EPZM) Up 3.8% Since Last Earnings Report?
by Zacks Equity Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss for the second quarter of 2021 despite its revenues beating estimates. As a result, stock price declines.
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -5.00% and 48.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.
Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -23.21% and 7.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme's (EPZM) Q4 Loss Wider than Expected, Sales Beat
by Zacks Equity Research
Epizyme (EPZM) incurs a wider-than-expected loss but beats sales estimates in the fourth quarter of 2020.
Epizyme (EPZM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -10.17% and 30.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More
by Kinjel Shah
Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
by Zacks Equity Research
Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.
Epizyme (EPZM) Down 3.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Epizyme (EPZM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of 9.84% and -40.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Epizyme (EPZM) Up 0.6% Since Last Earnings Report?
by Zacks Equity Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma
by Zacks Equity Research
The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.
Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.
Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the first quarter of 2020.
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.
Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?